← back to search

Christiane E. Angermann

Universitätsklinikum Würzburg · DE
Area of research
Cardiology and Cardiovascular Medicine · Surgery
Research interest
Research interests include Heart Failure Treatment and Management, Cardiovascular Function and Risk Factors, Cardiac pacing and defibrillation studies, and Cardiac Health and Mental Health.
h-index
55
citations
10,846
works
276
NIH funding
primary concept
Medicine
email

Recent publications

Treatment Effects of Empagliflozin in Hospitalized Heart Failure Patients Across the Range of Left Ventricular Ejection Fraction – Results from the EMPULSE Trial
European Journal of Heart Failure 2024cited by 22position: middledoi
Toward a Universal Definition of Etiologies in Heart Failure: Categorizing Causes and Advancing Registry Science
Circulation Heart Failure 2024cited by 16position: middledoi
Telemonitoring for Chronic Heart Failure: Narrative Review of the 20-Year Journey From Concept to Standard Care in Germany
Journal of Medical Internet Research 2024cited by 11position: middledoi
Multimorbidity in patients with acute heart failure across world regions and country income levels (REPORT-HF): a prospective, multicentre, global cohort study
The Lancet Global Health 2023cited by 38position: lastdoi
The Win Ratio Method in Heart Failure Trials: Lessons Learnt from EMPULSE
European Journal of Heart Failure 2023cited by 37position: middledoi
Global Variations According to Sex in Patients Hospitalized for Heart Failure in the REPORT-HF Registry
JACC Heart Failure 2023cited by 25position: middledoi
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
Nature Medicine 2022cited by 869position: middledoi
Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial
European Heart Journal 2022cited by 207position: middledoi
Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial
Circulation 2022cited by 141position: middledoi
Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the <scp>EMPULSE</scp> trial
European Journal of Heart Failure 2022cited by 78position: middledoi
Digital Technologies to Support Better Outcome and Experience of Care in Patients with Heart Failure
Current Heart Failure Reports 2022cited by 53position: middledoi
Global disparities in prescription of guideline-recommended drugs for heart failure with reduced ejection fraction
European Heart Journal 2022cited by 53position: middledoi
Sodium–glucose co‐transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the <scp>EMPULSE</scp> trial
European Journal of Heart Failure 2021cited by 103position: middledoi
Heart and brain interactions
Herz 2021cited by 41position: lastdoi
Pulmonary Artery Pressure-Guided Therapy in Ambulatory Patients with Symptomatic Heart Failure: The CardioMEMS European Monitoring Study for Heart Failure (MEMS-HF)
European Journal of Heart Failure 2020cited by 213position: firstdoi
Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study
The Lancet Global Health 2020cited by 207position: middledoi
Global Differences in Characteristics, Precipitants, and Initial Management of Patients Presenting With Acute Heart Failure
JAMA Cardiology 2020cited by 86position: middledoi
Mortality and morbidity 1 year after stopping a remote patient management intervention: extended follow-up results from the telemedical interventional management in patients with heart failure II (TIM-HF2) randomised trial
The Lancet Digital Health 2019cited by 61position: middledoi
Efficacy of a web-based intervention for improving psychosocial well-being in patients with implantable cardioverter-defibrillators: the randomized controlled ICD-FORUM trial
European Heart Journal 2019cited by 36position: middledoi
Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial
The Lancet 2018cited by 727position: middledoi
Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study
European Heart Journal 2017cited by 332position: middledoi
Rationale and design of a randomized, controlled multicentre clinical trial to evaluate the effect of bromocriptine on left ventricular function in women with peripartum cardiomyopathy
Clinical Research in Cardiology 2015cited by 62position: middledoi
"GOLD or lower limit of normal definition? a comparison with expert-based diagnosis of chronic obstructive pulmonary disease in a prospective cohort-study"
Respiratory Research 2012cited by 178position: middledoi
The Impact of Heart Failure on the Classification of COPD Severity
Journal of Cardiac Failure 2012cited by 48position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Sean P. Collins · Rutgers Cancer Institute11 papers (2020–2024)Jasper Tromp · National University of Singapore10 papers (2020–2024)Georg Ertl · Klinikum Bielefeld9 papers (2012–2023)Adriaan A. Voors · Centre Hospitalier Régional et Universitaire de Nancy6 papers (2021–2024)Jan Biegus · University of Wrocław6 papers (2021–2024)Jon Blatchford · King's College Hospital NHS Foundation Trust6 papers (2021–2024)Michael E. Nassif · Baim Institute for Clinical Research6 papers (2021–2024)João Pedro Ferreira · Institut des Sciences et technologies pour une Economie Circulaire des énergies bas carbone6 papers (2021–2024)John R. Teerlink · University of Glasgow6 papers (2021–2024)Piotr Ponikowski · University of Business in Wrocław6 papers (2021–2024)Mitchell A. Psotka · Inova Fairfax Hospital6 papers (2021–2024)Mikhail Kosiborod · Nagoya University6 papers (2021–2024)Ulf Dahlström · Linköping University5 papers (2020–2023)Kenneth Dickstein · Stavanger University Hospital5 papers (2020–2023)Mathieu Ghadanfar · Novartis (Switzerland)5 papers (2020–2023) · 5 papers (2020–2023)Anja Schweizer · Novartis (Switzerland)5 papers (2020–2023)Martina Brueckmann · University Hospital Heidelberg5 papers (2021–2024)John G.F. Cleland · Wythenshawe Hospital5 papers (2020–2023)Gerasimos Filippatos · German Centre for Cardiovascular Research5 papers (2020–2023)